Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Regenxbio (RGNX) Non-Current Receivables (2018 - 2025)

Regenxbio (RGNX) has 8 years of Non-Current Receivables data on record, last reported at $2.3 million in Q4 2025.

  • For Q4 2025, Non-Current Receivables rose 387.76% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $2.3 million, up 387.76%, while the annual FY2025 figure was $2.3 million, 387.76% up from the prior year.
  • Non-Current Receivables reached $2.3 million in Q4 2025 per RGNX's latest filing, down from $2.8 million in the prior quarter.
  • Across five years, Non-Current Receivables topped out at $4.5 million in Q3 2023 and bottomed at $404000.0 in Q3 2024.
  • Average Non-Current Receivables over 5 years is $1.8 million, with a median of $1.7 million recorded in 2022.
  • Peak YoY movement for Non-Current Receivables: plummeted 90.97% in 2024, then skyrocketed 584.41% in 2025.
  • A 5-year view of Non-Current Receivables shows it stood at $3.8 million in 2021, then tumbled by 59.98% to $1.5 million in 2022, then plummeted by 53.39% to $701000.0 in 2023, then tumbled by 32.38% to $474000.0 in 2024, then surged by 387.76% to $2.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Receivables were $2.3 million in Q4 2025, $2.8 million in Q3 2025, and $1.6 million in Q2 2025.